HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bogyeong Kim Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2018Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bogyeong Kim Research Topics

Disease

1Disease Susceptibility (Diathesis)
01/2021
1Atopic Dermatitis (Atopic Eczema)
10/2020
1Dermatitis
10/2020
1Albuminuria
01/2018
1Type 2 Diabetes Mellitus (MODY)
01/2018

Drug/Important Bio-Agent (IBA)

1NeurotoxinsIBA
01/2021
1CytokinesIBA
10/2020
1Interleukin-13IBA
10/2020
1Interleukin-17 (Interleukin 17)IBA
10/2020
1CeramidesIBA
10/2020
1Interleukin-4 (Interleukin 4)IBA
10/2020
1OxazoloneIBA
10/2020
1Interleukin-5 (Interleukin 5)IBA
10/2020
1Glucose (Dextrose)FDA LinkGeneric
01/2018
1LinagliptinIBA
01/2018
1LC15-0444IBA
01/2018

Therapy/Procedure

1Subcutaneous Injections
10/2020